ImmunityBio, Inc. Common Stock (IBRX) is a publicly traded Healthcare sector company. As of October 8, 2026, IBRX trades at $9.59 with a market cap of $10.27B and a P/E ratio of -10.70. IBRX moved -2.15% today. Year to date, IBRX is +382.67%; over the trailing twelve months it is +290.00%. Its 52-week range spans $1.83 to $12.43. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces IBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for IBRX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $9.59 |
| Market Cap | $10.27B |
| P/E Ratio | -10.70 |
| EPS | $-0.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.43 |
| 52-Week Low | $1.83 |
| Volume | 2.03M |
| Avg Volume | 0 |
| Revenue (TTM) | $165.79M |
| Net Income | $-992.42M |
| Gross Margin | 99.34% |
3 analysts cover IBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.